GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +16

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Klarisa Rikova, Ailan Guo, Qingfu Zeng et al. · Cell · 2007 · 2.3K citations · Full text

Medicine, Cancer Biology, Oncology +16